

[59] NT-219, A FIRST-IN- CLASS DUAL INHIBITOR OF STAT3 AND IRS1/2 IS OVERCOMING DRUG RESISTANCE

Hadas Reuveni, CEO, Tyrnovo LTD, Tel Aviv, Israel

Investment Rational

TyrNovo Ltd. (a Kitov Pharma subsidiary) is a pharmaceutical company that develops NT219 - an innovative first-in-class small molecule to overcome cancer drug resistance. Kitov and Tyrnovo's management team have a track record in bringing drugs to market through clinical development and regulatory submissions. Kitov's first drug, Consensi™, indicated for the simultaneous treatment of osteoarthritis pain and hypertension, was approved for marketing by the US FDA in May 2018 and is being commercialized through numerous licensing partnerships in the US as well as in China and Korea.

Business Strategy

Consensi™ generated revenues in the form of upfront and milestones payments received from our licensees, and is expected to generate royalties from sales in the near term. NT219, had a blockbuster potential in the oncology field as it demonstrated efficacy in various cancer types and in combinations with numerous cancer drugs.

Core Technology

NT219 is a first in class oncology drug candidate that targets two key proteins - IRS1/2 and STAT3- both play a major role in anti-cancer drug resistance. In pre-clinical models NT-219 demonstrated prevention and reversal of resistance to a wide array of approved oncology therapies such as Erbitux®, Tagrisso®, Tarceva®, Mekinist®, Zelboraf®, Afinitor®, as well as with chemotherapy, and Immuno-oncology agents.

Product Profile

NT219 is being developed for IV administration in combination with approved cancer therapies. IND submission and initiation of first-in-man clinical trials, in patients diagnosed with squamous cell carcinoma of the head and neck, in combination with Cetuximabare, are expected second half of 2019.

What's Next

IND-enabling preclinical work including GMP manufacturing and GLP tox studies are nearing completion. Clinical trial initiation is expected this year

